Terms: = Pancreatic cancer AND TRA AND Treatment
17 results:
1. A targetable pathway to eliminate tra-1-60+/tra-1-81+ chemoresistant cancer cells.
Tan L; Duan X; Mutyala P; Zhou T; Amin S; Zhang T; Herbst B; Askan G; Itkin T; Xiang Z; Michelassi F; Lieberman MD; Iacobuzio-Donahue CA; Leach SD; Evans T; Chen S
J Mol Cell Biol; 2023 Nov; 15(6):. PubMed ID: 37327088
[TBL] [Abstract] [Full Text] [Related]
2. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract] [Full Text] [Related]
3. The novel traIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
[TBL] [Abstract] [Full Text] [Related]
4. The CA19-9 and Sialyl-tra Antigens Define Separate Subpopulations of pancreatic cancer Cells.
Barnett D; Liu Y; Partyka K; Huang Y; Tang H; Hostetter G; Brand RE; Singhi AD; Drake RR; Haab BB
Sci Rep; 2017 Jun; 7(1):4020. PubMed ID: 28642461
[TBL] [Abstract] [Full Text] [Related]
5. A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of tra-8/DR5 Oligomers Predicts tra-8 Therapeutic Efficacy in Breast and pancreatic cancer Mouse Models.
Kim H; Buchsbaum DJ; Zinn KR
Mol Imaging Biol; 2016 Jun; 18(3):325-33. PubMed ID: 26552657
[TBL] [Abstract] [Full Text] [Related]
6. Calmodulin antagonists promote tra-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract] [Full Text] [Related]
7. Expression of the clustered NeuAcα2-3Galβ O-glycan determines the cell differentiation state of the cells.
Higashi K; Asano K; Yagi M; Yamada K; Arakawa T; Ehashi T; Mori T; Sumida K; Kushida M; Ando S; Kinoshita M; Kakehi K; Tachibana T; Saito K
J Biol Chem; 2014 Sep; 289(37):25833-43. PubMed ID: 25074924
[TBL] [Abstract] [Full Text] [Related]
8. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Forero-Torres A; Infante JR; Waterhouse D; Wong L; Vickers S; Arrowsmith E; He AR; Hart L; Trent D; Wade J; Jin X; Wang Q; Austin T; Rosen M; Beckman R; von Roemeling R; Greenberg J; Saleh M
Cancer Med; 2013 Dec; 2(6):925-32. PubMed ID: 24403266
[TBL] [Abstract] [Full Text] [Related]
9. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract] [Full Text] [Related]
10. Defined factors induce reprogramming of gastrointestinal cancer cells.
Miyoshi N; Ishii H; Nagai K; Hoshino H; Mimori K; Tanaka F; Nagano H; Sekimoto M; Doki Y; Mori M
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):40-5. PubMed ID: 20018687
[TBL] [Abstract] [Full Text] [Related]
11. Embryonic stem cell-like cells derived from adult human testis.
Mizrak SC; Chikhovskaya JV; Sadri-Ardekani H; van Daalen S; Korver CM; Hovingh SE; Roepers-Gajadien HL; Raya A; Fluiter K; de Reijke TM; de la Rosette JJ; Knegt AC; Belmonte JC; van der Veen F; de Rooij DG; Repping S; van Pelt AM
Hum Reprod; 2010 Jan; 25(1):158-67. PubMed ID: 19815622
[TBL] [Abstract] [Full Text] [Related]
12. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Kim H; Morgan DE; Buchsbaum DJ; Zeng H; Grizzle WE; Warram JM; Stockard CR; McNally LR; Long JW; Sellers JC; Forero A; Zinn KR
Cancer Res; 2008 Oct; 68(20):8369-76. PubMed ID: 18922909
[TBL] [Abstract] [Full Text] [Related]
13. tra-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
Derosier LC; Vickers SM; Zinn KR; Huang Z; Wang W; Grizzle WE; Sellers J; Stockard CR; Zhou T; Oliver PG; Arnoletti P; Lobuglio AF; Buchsbaum DJ
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3198-207. PubMed ID: 18089714
[TBL] [Abstract] [Full Text] [Related]
14. Combination treatment with tra-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
DeRosier LC; Buchsbaum DJ; Oliver PG; Huang ZQ; Sellers JC; Grizzle WE; Wang W; Zhou T; Zinn KR; Long JW; Vickers SM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
[TBL] [Abstract] [Full Text] [Related]
15. treatment with gemcitabine and tra-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract] [Full Text] [Related]
16. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
Kaliberov SA; Chiz S; Kaliberova LN; Krendelchtchikova V; Della Manna D; Zhou T; Buchsbaum DJ
Cancer Gene Ther; 2006 Feb; 13(2):203-14. PubMed ID: 16082379
[TBL] [Abstract] [Full Text] [Related]
17. Extended radical pancreatectomy for carcinoma of the head of the pancreas.
Nagakawa T; Konishi I; Ueno K; Ohta T; Kayahara M; Miyazaki I
Hepatogastroenterology; 1998; 45(21):849-54. PubMed ID: 9684146
[TBL] [Abstract] [Full Text] [Related]
